- Home
- EDTK vs SNSE Comparison
EDTK vs SNSE Comparison
Compare EDTK & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDTK
- SNSE
- Stock Information
- Founded
- EDTK 2013
- SNSE 2005
- Country
- EDTK China
- SNSE United States
- Employees
- EDTK N/A
- SNSE N/A
- Industry
- EDTK Other Consumer Services
- SNSE Biotechnology: Pharmaceutical Preparations
- Sector
- EDTK Real Estate
- SNSE Health Care
- Exchange
- EDTK Nasdaq
- SNSE Nasdaq
- Market Cap
- EDTK 15.5M
- SNSE 12.5M
- IPO Year
- EDTK 2020
- SNSE 2021
- Fundamental
- Price
- EDTK $1.09
- SNSE $0.45
- Analyst Decision
- EDTK
- SNSE Strong Buy
- Analyst Count
- EDTK 0
- SNSE 3
- Target Price
- EDTK N/A
- SNSE $4.33
- AVG Volume (30 Days)
- EDTK 7.3K
- SNSE 169.4K
- Earning Date
- EDTK 02-28-2025
- SNSE 03-03-2025
- Dividend Yield
- EDTK N/A
- SNSE N/A
- EPS Growth
- EDTK N/A
- SNSE N/A
- EPS
- EDTK N/A
- SNSE N/A
- Revenue
- EDTK $624,365.00
- SNSE N/A
- Revenue This Year
- EDTK N/A
- SNSE N/A
- Revenue Next Year
- EDTK N/A
- SNSE N/A
- P/E Ratio
- EDTK N/A
- SNSE N/A
- Revenue Growth
- EDTK N/A
- SNSE N/A
- 52 Week Low
- EDTK $0.84
- SNSE $0.38
- 52 Week High
- EDTK $1.27
- SNSE $1.94
- Technical
- Relative Strength Index (RSI)
- EDTK 55.47
- SNSE 38.52
- Support Level
- EDTK $1.02
- SNSE $0.44
- Resistance Level
- EDTK $1.11
- SNSE $0.49
- Average True Range (ATR)
- EDTK 0.05
- SNSE 0.04
- MACD
- EDTK 0.01
- SNSE -0.00
- Stochastic Oscillator
- EDTK 72.08
- SNSE 10.73
About EDTK Skillful Craftsman Education Technology Limited
Skillful Craftsman Education Technology Ltd provides online education and technology services in China. The services comprises of two aspects - Online vocational training and Virtual simulation experimental training. It covers a wide range of subjects, including mechanics, electronics, auto repair and construction. Majority of its revenues are generated from the People's Republic of China.
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing highly selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101, SNS-102, SNS-103, SNS-20.